Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Alabama STEM News.
Press releases published on May 8, 2025
Draganfly Announces First Quarter Results of 2025
GlobeNewswire
·
May 8, 2025
Vancouver, BC., May 08, 2025 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, is pleased to announce its first quarter …
Tarsus to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 8, 2025
IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that management plans to participate in the following upcoming investor conferences: Bank of America Securities 2025 Health Care Conference on …
Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering
GlobeNewswire
·
May 8, 2025
Hopewell, New Jersey, May 08, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally …
BioSyent Schedules First Quarter Earnings Release for May 15, 2025
GlobeNewswire
·
May 8, 2025
MISSISSAUGA, Ontario, May 08, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2025 on Thursday, May 15, 2025 after market hours. A presentation …
Galecto Reports First Quarter 2025 Operating and Financial Results
GlobeNewswire
·
May 8, 2025
BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter …
Theriva Biologics Announces Closing of $7.5 Million Public Offering
GlobeNewswire
·
May 8, 2025
ROCKVILLE, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, …
Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
GlobeNewswire
·
May 8, 2025
On track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinson’s disease in Q4 2025 Strengthened balance sheet with recent financing Advancing innovative POZ Platform across multiple therapeutic modalities Two new seasoned …
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025 Nature Microbiology publication highlights preclinical data and the potential of CD388 as a potent, universal antiviral for …
PacBio Announces First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results: Q1 2025 Q1 2024 Revenue $37.2 million $38.8 million Instrument revenue $11.0 million …
Microchip Technology Announces Quarterly Cash Dividend on Common Stock of 45.5 Cents Per Share
GlobeNewswire
·
May 8, 2025
CHANDLER, Ariz., May 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MCHP) – Microchip Technology Incorporated, a leading provider of smart, connected, and secure embedded control solutions, today announced that its Board of Directors declared a quarterly cash …
Microchip Technology Announces Financial Results For Fourth Quarter and Fiscal Year 2025
GlobeNewswire
·
May 8, 2025
For the quarter ended March 31, 2025 Net sales of $970.5 million, declined 5.4% sequentially and 26.8% from the year ago quarter. The midpoint of our guidance provided on February 6, 2025 was net sales of $960.0 million. On a GAAP basis: gross profit of …
INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update
GlobeNewswire
·
May 8, 2025
BOCA RATON, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces its financial results for the …
PubMatic Announces First Quarter 2025 Financial Results; Board of Directors Authorizes $100M Expansion of Share Repurchase Program
GlobeNewswire
·
May 8, 2025
Delivered revenue and adjusted EBITDA ahead of guidance; Revenue from omnichannel video, including CTV, grew 20% and was 40% of total revenue; CTV revenue grew over 50% year-over-year; and Supply Path Optimization represented a record 55%+ of total …
Oculis Reports Q1 2025 Financial Results and Provides Company Update
GlobeNewswire
·
May 8, 2025
The recent R…
Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15
GlobeNewswire
·
May 8, 2025
DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system ( …
Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
Six posters presented at the American Association for Cancer Research (AACR) annual meeting Appointment of Dr. Sabeen Mekan as Senior Vice President, Clinical Development Reported $321.6 million in cash resources as of March 31, 2025 (compared to $324.2 …
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
GlobeNewswire
·
May 8, 2025
Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to date Initiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expected in Q3 2025, with topline data from both 4FRONT-1 and …
Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 8, 2025
Regulatory Interactions and Commercial, Medical, and Corporate Preparations On-Track for Paltusotine New Drug Application with September 25, 2025 PDUFA Date CALM-CAH Phase 3 Study of Atumelnant for the Treatment of Adults with Congenital Adrenal …
Sprout Social Announces First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
CHICAGO, May 08, 2025 (GLOBE NEWSWIRE) -- Sprout Social, Inc. (“Sprout Social”, the “Company”) (Nasdaq: SPT), an industry-leading provider of cloud-based social media management software, today announced financial results for its first quarter ended March …
Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 8, 2025
Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to complete enrollment in the second quarter of 2025 …